{"nctId":"NCT02073448","briefTitle":"Efficacy and Safety Study of GK530G Versus CD0271 0.1% Gel and CD1579 2.5% Gel in the Treatment of Acne Vulgaris.","startDateStruct":{"date":"2014-03"},"conditions":["Acne Vulgaris"],"count":417,"armGroups":[{"label":"GK530G","type":"EXPERIMENTAL","interventionNames":["Drug: GK530G"]},{"label":"CD0271","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: CD0271"]},{"label":"CD1579","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: CD1579"]}],"interventions":[{"name":"GK530G","otherNames":["Fixed-dose combination gel of Adapalene and Benzoyl Peroxide"]},{"name":"CD0271","otherNames":["Adapalene 0.1% Gel"]},{"name":"CD1579","otherNames":["Benzoyl Peroxide 2.5% Gel"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Men and women at the age of 12 or older at the Screening visit.\n* Those with clinical diagnosis of acne vulgaris with more than 20 noninflammatory lesions (open and closed comedones) and 12 to 100 (inclusive) inflammatory lesions (papules, pustules and nodules) on the face (forehead, both cheeks, nose and chin).\n\nExclusion Criteria:\n\n* Those with more than two nodular acne lesions or any cysts.\n* Those with the diagnosis of any acne conglobata, any acne fulminans, any chloracne, or any drug induced acne.\n* Those who have clinically significant abnormal findings or conditions on skin other than acne such as atopic dermatitis, perioral dermatitis, or rosacea that potentially interfere with study assessments according to Investigator's judgment.","healthyVolunteers":false,"sex":"ALL","minimumAge":"12 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percent Changes From Baseline in Total Lesion Counts","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"68.6","spread":null},{"groupId":"OG001","value":"82.7","spread":null},{"groupId":"OG002","value":"81.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent of Subjects With Adverse Events","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27.7","spread":null},{"groupId":"OG001","value":"44.8","spread":null},{"groupId":"OG002","value":"37.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Local Tolerability (Erythema)","description":"Highest severity of local tolerability scores worse than Baseline","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"78","spread":null},{"groupId":"OG001","value":"32","spread":null},{"groupId":"OG002","value":"20","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Local Tolerability (Scaling)","description":"Highest severity of local tolerability scores worse than Baseline","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"105","spread":null},{"groupId":"OG001","value":"37","spread":null},{"groupId":"OG002","value":"24","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"33","spread":null},{"groupId":"OG001","value":"9","spread":null},{"groupId":"OG002","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Local Tolerability (Dryness)","description":"Highest severity of local tolerability scores worse than Baseline","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"113","spread":null},{"groupId":"OG001","value":"44","spread":null},{"groupId":"OG002","value":"29","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31","spread":null},{"groupId":"OG001","value":"6","spread":null},{"groupId":"OG002","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Local Tolerability (Pruritus)","description":"Highest severity of local tolerability scores worse than Baseline","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"61","spread":null},{"groupId":"OG001","value":"24","spread":null},{"groupId":"OG002","value":"24","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Local Tolerability (Stinging/Burning)","description":"Highest severity of local tolerability scores worse than Baseline","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"106","spread":null},{"groupId":"OG001","value":"49","spread":null},{"groupId":"OG002","value":"21","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"76","spread":null},{"groupId":"OG001","value":"11","spread":null},{"groupId":"OG002","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":101},"commonTop":["Nasopharyngitis","Skin irritation","Eczema","Dysmenorrhoea","Skin papilloma"]}}}